Merck (MRK)

Latest stories mapped to MRK

Everything Newsig has mapped to MRK, newest first — no importance filter. Topic pages list critical and high-importance stories only.

• 2026-09-25 Merck pulls BLA for antibody-drug conjugate I-DXd for small cell lung cancer
• 2026-09-25 Daiichi Sankyo and Merck withdraw lung cancer drug application
• 2026-09-24 Merck Welireg, Eisai Lenvima combo approved for kidney cancer
• 2026-09-24 Merck’s diabetic macular edema therapy succeeds in Phase 2b/3 trial
• 2026-09-24 Merck’s remigromig meets primary endpoint in diabetic macular edema trial
• 2026-09-22 Merck says FDA approved label update for PAH therapy Winrevair
• 2026-09-21 4 stocks to watch on Monday: HPQ, PFE, MRK, and MRVL
• 2026-09-21 Merck secures Japanese approval for subcutaneous Keytruda
• 2026-09-19 Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
• 2026-09-17 Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise
• 2026-09-13 Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial